Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors.
- DOI
- 10.1007/s10549-025-07879-0
- Published
- 2026 Feb 11
- Container
- Breast cancer research and treatment
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-025-07879-0,
title = {Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors.},
author = {Brown NL and Howell SJ and Papantoniou D and Eriksson O and Bergqvist M and Williams A and Kavanagh A and Backlund A and Albu-Kareem A and Elinder E and Larsson K and Uminska M and Ekholm M},
year = {2026},
journal = {Breast cancer research and treatment},
doi = {10.1007/s10549-025-07879-0},
url = {https://doi.org/10.1007/s10549-025-07879-0}
}RIS
TY - JOUR TI - Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors. AU - Brown NL AU - Howell SJ AU - Papantoniou D AU - Eriksson O AU - Bergqvist M AU - Williams A AU - Kavanagh A AU - Backlund A AU - Albu-Kareem A AU - Elinder E AU - Larsson K AU - Uminska M AU - Ekholm M PY - 2026 JO - Breast cancer research and treatment DO - 10.1007/s10549-025-07879-0 UR - https://doi.org/10.1007/s10549-025-07879-0 ER -
APA
NL, B., SJ, H., D, P., O, E., M, B., A, W., A, K., A, B., A, A., E, E., K, L., M, U., & M, E. (2026). Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-025-07879-0
Source records
- pubmed · retrieved 2026-09-27T07:02:01.559Z